Key facts
- It has raised $12.6M across 2 recorded rounds; the latest was Seed Round ($831K) in Oct 2020.
- Notable investors include National Institutes of Health, Invest Nova Scotia, Elevate Capital, Business Oregon, Alliance of Angels — 10 tracked in total.
- Veana Therapeutics has filed 2 Form Ds with the SEC since 2018, most recently Nov 2020 ($831K sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Veana Therapeutics
Funding rounds
2 roundsAbout Veana Therapeutics
Operator of an early clinical-stage company intended to develop oral mitochondrial inhibitors for treating various cancers. The company offers a safe and effective oral therapeutic intended to kill cancer cells selectively and is based on orally bioavailable anti-cancer agents that kill cancer cells and stimulate the immune system to boost the immunological responses in cancer patients, enabling patients to have a better quality of life during and after the treatment of cancer.
- Sector
- Healthcare
- HQ
- Portland, OR, United States
- Founded
- 2012
- Employees
- 2
- Website
- veana-therapeutics.com/
- Ownership
- Privately Held (backing)
Veana Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Veana Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Veana Therapeutics in its N-PORT filings yet. We sweep new filings monthly.